Related Experiment Video
Updated: May 28, 2026
06:00
Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
Published on: December 30, 2025
Management of hepatic encephalopathy
G Wright1, A Chattree, R Jalan
1University College London Institute of Hepatology, The Royal Free Hospital, Pond Street, London NW3 2PF, UK.
International Journal of Hepatology
|October 14, 2011
Summary
Hepatic encephalopathy (HE) is a serious liver disease complication. Current treatments focus on lowering ammonia, but novel therapies are needed for chronic and advanced cases.
Area of Science:
- Hepatology
- Neuroscience
- Internal Medicine
Background:
- Hepatic encephalopathy (HE) is a significant neuropsychiatric complication of liver disease.
- HE is linked to high rates of morbidity and mortality.
- Current therapeutic strategies primarily focus on reducing plasma ammonia levels.
Purpose of the Study:
- To review current evidence for managing chronic hepatic encephalopathy.
- To discuss interventions for acute and advanced stages of HE.
- To highlight the need for novel therapeutic approaches in HE management.
Main Methods:
- Literature review of existing studies on hepatic encephalopathy treatments.
- Analysis of evidence for ammonia-lowering therapies.
- Discussion of emerging and novel therapeutic strategies.
Main Results:
- Plasma ammonia reduction is the cornerstone of current HE management.
- Evidence supports various interventions for general, chronic, acute, and advanced HE.
- There is an ongoing need for the development of new therapeutic options.
Conclusions:
- Effective management of hepatic encephalopathy requires addressing ammonia levels.
- A range of interventions can be employed for different stages of HE.
- Further research into novel therapies is crucial for improving patient outcomes.
Related Concept Videos
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...